Lupus & antiphospholipid syndrome
Early belimumab accelerates renal response and reduces glucocorticoid exposure in lupus nephritis: a multicentre propensity-matched study
Main finding · CRRResult — go to the resultOdds ratio 2.81 95% CI 1.30–6.29Authors' conclusion
Early belimumab combination therapy accelerates CRR and reduces GC exposure.
Study context
- Population
- Consecutive adults with biopsy-proven lupus nephritis (LN), Italian lupus referral centrespropensity-matched
- Participants
- 91 vs 91
- Exposure
- Early belimumab plus standard-of-care (SoC) vs SoC alone
- Belimumabn = 91
- SoCn = 91reference
- Outcome
- CRR (2019 EULAR/EDTA)
- Follow-up
- 6 months
Methodological detailsmulticentre, propensity-score matched, historical control cohort (1990-2016)
- Multicentre
- Propensity-score matched
- Historical control cohort (1990-2016)
Main finding
CRR
Odds ratio
2.81
95% CI 1.30–6.29
P = 0.005
By group
Belimumabvs SoC
OR 2.81 (95% CI 1.30–6.29); P = 0.005
As reported in the abstract
Observational data: associations, not effects.
Further findings
Time to CRR
P < 0.01
GC dose at CRR
P = 0.018
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Independent predictors of earlier CRR (Cox regression) | 1.70 (1.11–2.62) | P = 0.016 | |
| 0.20.5125Hazard ratio (log scale) |
- Complete renal response (CRR) · 12 months
- P = 0.87
CRR · 12 months
- Response rates similar
Independent predictors of earlier CRR (Cox regression)
- Baseline proteinuria, HR per g/24 h increase 0.89 (95% CI 0.80, 0.98), P = 0.019
Original publication
Early belimumab accelerates renal response and reduces glucocorticoid exposure in lupus nephritis: a multicentre propensity-matched study. Rheumatology (Oxford). Published 25 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →